The Spouse: The Unnamed Victim of Military Injury — Erased by Every System Meant to Protect Her

Written By Jacqualine Roche

Introduction

This document concerns the partners and spouses of Australian Defence Force veterans with quinoline-induced neurological injury. The population addressed is predominantly female. The pronoun "she" is used throughout to reflect that demographic reality, without implying that male partners are unaffected or that their experience is without significance.

This document addresses spouses as subjects of harm in their own right — not as carers, not as secondary figures in the veteran's clinical story, and not as collateral damage to be acknowledged in passing. The harm sustained by this population is direct, severe, long-term, and in many cases irreversible. It also has a specific and traceable cause: neurological injury in the veteran, produced by drugs administered by the Australian government without adequate informed consent, monitoring, or follow-up care.

That causal chain has not been followed to its full consequences. In research, in clinical practice, in DVA policy, in family law, and in every institutional framework that might be expected to respond, the spouse is not a recognised subject. Her harm has no clinical category, no compensation pathway, no forensic precedent, and no policy framework. It has, in most cases, no name.

The document proceeds in two parts. The first is a clinical and social profile of the harm as it presents across the domains of mental health, physical health, financial circumstances, social functioning, legal exposure, and parenting. The second names, without mitigation, what is structurally absent in every institution and framework that should respond to that harm.

A formal evidential register is appended. Readers assessing the document for legal, policy, or clinical purposes should consult it.

Part One: Clinical and Social Profile

1. The Pharmacological Context

The harm documented in this profile originates in a specific pharmacological event: the administration of quinoline antimalarial drugs — principally mefloquine (Lariam) and tafenoquine — to ADF personnel, in many cases as part of clinical trials conducted between 1998 and 2002 in Papua New Guinea, East Timor, and Australia.

Mefloquine was found to be neurotoxic in 2006. Subsequent research established that it can cause a chronic central nervous system toxicity syndrome, with symptoms including anxiety, depression, psychosis, paranoia, persecutory delusions, dissociative episodes, anterograde amnesia, tinnitus, vestibular disturbance, and sleep disorder. These effects are not exclusively acute. They can be chronic, persistent, and progressive. Tafenoquine has been found to be more neurotoxic than mefloquine. These findings are documented in McCarthy (2015), a peer-reviewed analysis of mefloquine neurotoxicity and risk in the ADF.

The psychiatric side effects of mefloquine intoxication include, specifically, paranoid ideation, dissociative psychosis, and anterograde amnesia. Exposure has been associated with acts of violence and with suicide. These are not peripheral or rare effects. They are documented in the peer-reviewed literature and have been the subject of a forensic psychiatric analysis by Nevin and Ritchie (2013) examining their potential application in legal proceedings.

The Australian Senate inquiry into the use of mefloquine and tafenoquine in the ADF, which reported in December 2018, received over one hundred submissions from veterans attributing chronic and complex symptoms to these drugs. The Quinism Foundation has described the resulting condition as chronic quinoline encephalopathy — a serious and potentially life-threatening brain disorder — and has supported Australian veterans' calls for compensation.

This pharmacological profile is the foundation of the spouse's harm. What she lived with was not a characterological tendency toward violence or control. It was, in whole or in significant part, the behavioural expression of a drug-induced neurological injury sustained by her partner in the course of his military service. That distinction has consequences for clinical assessment, for legal proceedings, for risk management, and for the attribution of responsibility — consequences that have not been worked through in any institutional context.

A further consequence of this pharmacological specificity is the misattribution problem. In many cases, the veteran's condition has been diagnosed and treated as PTSD. PTSD and quinoline-induced neurological injury share overlapping symptom profiles. They are not the same condition. PTSD-calibrated treatment — including trauma-focused cognitive behavioural therapy and EMDR — does not address acquired neurological injury. A veteran receiving PTSD treatment for a condition that is wholly or partly neurological in origin is not receiving treatment that resolves the underlying cause of dangerous behaviour. The spouse's risk does not diminish because the veteran is in treatment. It may persist for the duration of the relationship and beyond.

2. Chronic Trauma and Nervous System Dysregulation

A woman who has lived for months or years alongside a person with quinoline-induced neurological injury develops trauma responses that are clinically well-understood and often severe. The chronic, unpredictable, and inescapable nature of the threat does not permit the nervous system to return to baseline. The result is persistent dysregulation: a nervous system chronically calibrated to danger, operating in that state not because the danger is imagined, but because for an extended period it was real.

This dysregulation does not resolve automatically with separation or with the passage of time. Women in this situation report that hypervigilance persists long after the relationship has ended — scanning for threat in objectively safe environments, difficulty sleeping without checking exits, sustained physiological arousal without any current external cause. These are not symptoms of an anxious temperament or a pre-existing vulnerability. They are the sequelae of sustained exposure to a genuinely dangerous environment.

The clinical presentation meets the diagnostic criteria for post-traumatic stress disorder. In cases where the trauma has been chronic, interpersonal, and without viable exit, the presentation may meet the criteria for complex PTSD as defined in ICD-11 — a diagnostic category that accounts for the affective dysregulation, disturbances in self-concept, and relational consequences that accompany prolonged interpersonal trauma. The general research literature on IPV and trauma responses confirms that even moderate levels of sustained interpersonal violence are associated with the affective and behavioural dysregulation characteristic of complex PTSD. The theatre in which this PTSD was acquired was not a combat zone. It was a domestic one. That fact has not registered in any institutional framework governing the recognition, treatment, or compensation of this population.

3. Hypervigilance About Children

Women who share custody arrangements following separation describe persistent and specific concern about their children's safety during contact periods with the affected veteran. This concern is grounded in direct observation. These women have witnessed dissociative rage states, paranoid episodes, and incidents of sleep-related violence. They have, in many cases, intervened directly to protect children during such episodes. Their assessment of ongoing risk is not speculative. It is evidence-based, derived from sustained exposure to the behaviour in question.

In family court proceedings, this concern is frequently pathologised. It is characterised as over-protectiveness, attributed to the mother's own mental health difficulties, or framed as a tactical instrument in contested custody litigation. The phenomenon is well-documented in the broader domestic violence and family court literature. A 2023 scoping reviewfound that legal professionals routinely lacked knowledge of the complexities of domestic violence, that child abuse claims were minimised or dismissed, and that mothers were blamed for the abuse they had experienced. Research on custody evaluations in high-conflict situations confirms that a protective parent's defensive reactions, when present alongside genuine domestic violence, should not be labelled as parental alienation — yet frequently are.

In the quinoline context, this dynamic is compounded by the complete absence of any clinical or legal framework that would allow the court to situate the veteran's behaviour within a neurological injury model. The court has no basis on which to understand that the behaviour the mother witnessed and reported is pharmacologically grounded, that it does not respond to PTSD treatment, and that the episodic presentation — periods of apparently normal functioning alternating with dangerous episodes — is consistent with the documented neuropsychiatric profile of quinoline toxicity. The mother who knows this, because she lived it, has no institutional language with which to say it in a way the court is equipped to receive.

4. Financial Harm

The financial consequences sustained by women in this situation are frequently severe, compounding, and long-lasting. They include:

  • Loss of the veteran's income through medical discharge, incapacity, or sustained employment instability.

  • Legal costs associated with family court proceedings, apprehended violence orders, and related civil and criminal litigation — in many cases accumulating over years or decades.

  • The cost of relocating for safety, in some cases multiple times, disrupting employment, schooling, and community connection.

  • The cost of raising children largely or entirely alone, often without reliable or adequate child support.

  • Loss of shared assets in the context of family breakdown, including superannuation, property, and business interests built during the relationship.

  • Reduced personal employment capacity resulting from the demands of crisis management and the woman's own trauma-related health consequences — including the cognitive and functional impairments associated with chronic PTSD.

These costs are not incidental to the harm. They are structural components of it. They compound the physical and psychological injury, constrain access to legal remedy, and in a significant number of cases produce long-term economic disadvantage from which recovery is partial at best.

No financial recognition, compensatory mechanism, or support pathway currently exists within DVA frameworks or any other Commonwealth instrument for women in this position.

5. Social Isolation

Paranoid and controlling behaviour patterns associated with quinoline toxicity frequently include systematic restriction of the partner's social contacts. This restriction is rarely abrupt. It is incremental — a comment about a friendship, a demand withdrawn and then reinstated, a pattern of consequences attached to outside contact until the contact ceases. Over time, friendships are curtailed, family relationships are disrupted, and community connections are eroded. The woman's world contracts.

Social isolation of this kind serves compounding functions within a pattern of domestic harm. It reduces her access to support and information. It increases her economic and emotional dependence. It diminishes the probability that the behaviour will be observed, named, or reported by people outside the household. It is both a mechanism and a consequence of harm, and it is a recognised risk factor for escalation of domestic violence over time. The American Psychiatric Association notes that exposure to chronic trauma contributes to emotional dysregulation, fear, and social isolation, which further exacerbate mental health conditions.

For women in the quinoline context, social isolation has an additional dimension that has not been addressed in any clinical or policy framework. The behaviour producing the isolation may not have been understood — by the woman herself, by her family, or by any professional she encountered — as neurologically driven. It may have been attributed to the veteran's personality, to combat stress, to PTSD, to relationship dynamics, or to her own behaviour as a partner. The specific pharmacological cause was unlikely to have been named during the years in which the isolation was occurring, and the woman living through it had no access to the category that would have made it legible.

6. Apprehended Violence Orders and Family Court Proceedings

These are distinct legal instruments with different purposes, different evidentiary standards, and different practical consequences for women in this situation. They are treated separately here because the gaps affecting each are not identical.

Apprehended Violence Orders

An AVO is a protective instrument issued by a court on the basis of apprehended fear of violence or harassment. It carries a lower evidentiary threshold than criminal or family court proceedings. In theory, it provides immediate protection. In practice, its utility for women whose partners have quinoline-induced neurological injury is constrained by several factors.

The episodic nature of the veteran's dangerous behaviour — periods of apparently normal functioning alternating with acute episodes — makes it difficult to establish the sustained pattern of threat that AVO applications typically require. A veteran who presents as composed and functional at the time of proceedings, and whose behaviour is neurologically driven rather than characterological, may not appear to a magistrate as a person from whom protection is warranted. There is no clinical framework available to the court that would explain the neurological basis of the risk. There is no precedent. There is no expert witness practice in this area.

Furthermore, an AVO does not resolve the neurological injury producing the dangerous behaviour. Compliance with an AVO requires the veteran's cooperation and insight. Where the behaviour derives from a drug-induced brain injury that the veteran does not recognise or acknowledge, the protective instrument rests on a foundation it cannot support.

Family Court Proceedings

Courts determining parenting arrangements for children are required to treat the safety of the child as the paramount consideration. In practice, courts operating without awareness of quinoline toxicity may interpret the veteran's periods of apparently normal functioning as evidence of safety — without access to any clinical framework explaining that the neurological injury producing the dangerous behaviour is persistent, does not respond to PTSD-calibrated treatment, and is not reliably indicated by observable presentation at a given moment.

The mother who raises concerns about quinoline-related risk faces a specific and documented disadvantage. Research on family court proceedings involving domestic violence consistently finds that protective mothers are perceived as exaggerating, as motivated by tactical considerations, or as projecting their own mental health difficulties onto the other parent. A 2023 PMC study on IPV survivors navigating family court found that legal abuse and harmful judicial responses are directly associated with elevated PTSD and depression in court-involved mothers. The Journal of Veterans Studies has documented that when combat-related PTSD is present, courts and practitioners struggle to distinguish PTSD symptoms from deliberate IPV tactics — and that when they fail to do so, victims do not receive needed support.

In the quinoline context, this dynamic is compounded by the complete absence of any clinical or legal framework within which the court can evaluate the concern on its own terms.

The forensic position of the mother's legal representative is correspondingly constrained:

  • There is no clinical category for quinoline-related domestic harm.

  • There is no DVA acknowledgement of the nexus between quinoline toxicity and domestic violence.

  • There is no published Australian case in which mefloquine or tafenoquine toxicity has been successfully introduced as an explanatory factor in family court proceedings.

  • There is no established expert witness framework for quinoline neurological injury and its domestic consequences in Australian forensic practice.

Each woman who brings proceedings in this context does so without the accumulated weight of prior decisions. Her legal representative must construct the argument from first principles. The evidentiary vacuum is reproduced in every proceeding, because nothing has yet been established that would fill it.

7. Lifelong Health Consequences

The health consequences for women who have lived with quinoline-affected veterans are consistent with the general research literature on intimate partner violence and chronic interpersonal trauma. A 2024 systematic review published by the National Academies established multiple long-term health outcomes associated with IPV, including cardiovascular risks, endocrine disorders, immune disruption, and a range of mental health consequences. A 2025 paper in Frontiers in Global Women's Health confirmed that IPV survivors face increased risk of chronic conditions through systemic inflammation and dysregulation of the body's stress-response systems. The health consequences for this population include:

  • Major depressive disorder.

  • Post-traumatic stress disorder and complex PTSD.

  • Anxiety disorders and panic disorder.

  • Chronic pain conditions associated with sustained physiological hyperarousal and HPA axis dysregulation.

  • Cardiovascular disease associated with prolonged stress exposure — including elevated risk of hypertension and coronary artery disease documented in longitudinal studies of IPV survivors.

  • Disruption of immune function, associated with chronic cortisol elevation and systemic inflammation.

  • Persistent sleep disturbance as a long-term sequela.

  • Reduced life expectancy.

  • Alcohol and substance use as coping mechanisms.

  • Impaired parenting capacity as a consequence of unresolved trauma.

  • Neurological consequences including cognitive impairment and memory disruption associated with chronic trauma exposure.

These are not the consequences of a difficult relationship. They are the consequences of sustained exposure to a dangerous environment with a specific, identifiable, pharmacological cause. The causal chain is traceable: from a government decision to administer potent neurotoxic drugs without adequate informed consent, monitoring, or follow-up care; to neurological injury in the veteran; to the behavioural expression of that injury in the domestic environment; to the physical and psychological harm sustained by the woman living in that environment.

That chain has not been traced, in any institutional or compensatory framework, to the woman at its end.

One further observation is warranted. Impaired parenting capacity appears in the list above as a documented health consequence of chronic trauma exposure. It is the same condition that family courts may record as a finding against the mother in proceedings involving custody or parenting arrangements. The system that fails to recognise the cause of the impairment is the same system that may penalise her for it. This circularity is not incidental. It is a structural feature of the institutional landscape this population navigates.

8. Women Who Remained

The preceding sections have addressed primarily women who separated from the affected veteran. The frameworks of custody, relocation, AVO proceedings, and legal aftermath presuppose separation. That framing is incomplete.

A significant number of women did not separate, or did not separate until many years or decades had passed. Their position differs materially from those who left early, and it has received no attention in any clinical, policy, or research context specific to this population.

Many women remained not because the environment was safe, but because no viable exit existed. The systems around them provided no recognition of what was happening, no language with which to name it, and no framework within which to seek protection or assistance. The pharmacological basis of the veteran's behaviour was not publicly identified until the mid-2000s at the earliest. The Australian Senate inquiry did not report until December 2018. DVA did not establish its Anti-Malarial Health Assessment program until after that inquiry — and that program was designed for veterans, not for their partners.

A woman living within this environment from 2000 onwards had no access, for many years, to the category that would have made the harm legible. She may have sought help from general practitioners, mental health services, domestic violence services, police, or courts during those years. The responses she received would have been calibrated to ordinary domestic violence or mental illness frameworks — frameworks that did not account for the specific neurological origin of the behaviour she was describing, and that were therefore unable to provide her with an accurate assessment of the risk she faced or an appropriate intervention.

For women who lived through this harm for extended periods — from, for example, 2000 to 2017 — the consequences are now accumulating in bodies that carried that load for nearly two decades without recognition, without appropriate clinical response, and without any institutional acknowledgement that what was happening to them was connected to a government drug administration decision. Recognition, where it has arrived at all, has arrived after the harm was done.

The cumulative exposure effect in this cohort — the relationship between duration of exposure and severity of long-term health consequences — has not been studied. What can be stated is that the general IPV literature consistently finds that severity and duration of exposure are associated with more severe and more persistent health consequences. There is no reason to expect this population to differ from that finding, and every reason to expect that the absence of any accurate framework during the years of harm compounded the injury.

Part Two: What Is Missing

This section names the structural absences in research, clinical categorisation, policy, law, and institutional recognition that render the harm documented in Part One invisible to the systems that should respond to it. These are not oversights that can be corrected incrementally. They constitute a systematic gap between the existence of a harmed population and the institutional capacity to see, name, or respond to it.

1. Research

There are no studies directly examining the partner cohort of ADF quinoline-exposed veterans. No study has measured the prevalence of trauma presentations in this population. No study has documented their health outcomes. No study has examined the relationship between duration of exposure to quinoline-related domestic harm and severity of long-term sequelae. No longitudinal data exists. No population has been identified, enumerated, or followed.

The inferential basis on which this document draws — the general research literature on intimate partner violence and chronic interpersonal trauma — is the only available basis. That inference is reasonable and defensible. It is not a substitute for direct evidence, and it cannot support the level of specificity that legal, policy, and clinical applications require.

The absence of direct research is not accidental. It reflects a failure of research attention that is itself a form of institutional non-recognition. The population exists. The harm exists. The research does not.

Additionally:

  • No study has examined the specific psychological dynamics of living with a partner whose dangerous behaviour is episodic, neurologically driven, and publicly unrecognised.

  • No study has examined the experience of women who sought help from clinical, legal, or domestic violence services during the years before quinoline toxicity was publicly named, and what those encounters produced.

  • No study has examined children of quinoline-affected veterans as a population — their developmental exposure, intergenerational trauma, or secondary harm from witnessing parental violence.

  • No study has examined the cumulative exposure effect for women who remained in the relationship for extended periods.

2. Clinical Categories

There is no clinical category for quinoline-related domestic harm. There is no diagnostic sub-specifier, no recognised exposure category, and no clinical guideline that situates a woman's trauma presentation within a causal framework linking it to the veteran's drug-induced neurological injury.

The consequences of this absence are practical and immediate:

  • A treating clinician has no established framework within which to record, code, or treat the presentation according to its actual cause.

  • The woman's PTSD is recorded as PTSD, without any notation connecting it to a specific environment and a specific pharmacological cause.

  • The causal chain — from government drug administration to veteran neurological injury to partner trauma — is severed at the point of clinical documentation.

  • The misattribution of the veteran's condition to PTSD rather than acquired brain injury, and the clinical consequences of that misattribution for the woman's ongoing risk, are not addressed in any clinical guideline or practice framework.

Whether Complex PTSD, as currently coded in ICD-11, is being applied to this population is unknown. There is no data on diagnosis rates, treatment access, or clinical outcomes for this cohort.

3. DVA Recognition and Policy

The Department of Veterans' Affairs has acknowledged quinoline toxicity as a cause of harm in veterans, recognising mefloquine and tafenoquine as potential causal factors in sixteen conditions. It has not acknowledged the nexus between that harm and domestic violence experienced by partners. It has established no mechanism by which a woman can seek recognition of harm independent of the veteran's claim status or cooperation.

Specifically:

  • There is no DVA compensation pathway for partners of quinoline-affected veterans.

  • There is no DVA treatment framework specifically calibrated to this population.

  • The Anti-Malarial Health Assessment program, which ran until July 2023, was designed for veterans. No equivalent program was created for their partners. The asymmetry — a targeted assessment pathway for veterans, nothing for partners — has not been acknowledged or justified by DVA.

  • Open Arms and other DVA-adjacent mental health services have not, to the knowledge of this document, developed treatment protocols or clinical guidance specific to the partner cohort.

  • Partners of quinoline-affected veterans are not, in any current DVA policy framework, a recognised population.

The Royal Commission into Defence and Veteran Suicide examined the mental health and welfare of veterans and their families. Whether the domestic consequences of quinoline toxicity for partners fell within its terms of reference, and whether it received or considered evidence on this point, has not been established.

4. Legal and Forensic Frameworks

No legal precedent exists in Australia in which quinoline toxicity has been introduced as a recognised explanatory factor in family court proceedings, AVO applications, or criminal proceedings for family violence.

No forensic clinical framework exists for expert evidence on quinoline neurological injury and its domestic consequences in Australian legal proceedings.

No standard of practice has been established for courts or legal practitioners assessing risk where the dangerous behaviour has a drug-induced neurological origin.

This absence has direct practical consequences. Each woman who brings proceedings does so without the accumulated weight of prior decisions or established expert frameworks. Each legal representative must construct the argument from first principles, without precedent, without a recognised clinical category, and without DVA acknowledgement of the nexus.

In other jurisdictions and in relation to other government-administered substances, causal chains from drug or toxin exposure to harm in family members have been legally established. Agent Orange litigation in the United States established liability for harm to veterans' families. Asbestos litigation has established compensable harm for family members exposed through the clothing of workers. Thalidomide litigation established government and manufacturer responsibility for harm caused by an inadequately tested drug. These precedents do not translate directly to the quinoline context, but they establish that the legal architecture for this kind of claim exists in principle. Its absence in the quinoline context is not an inevitability. It is a gap.

5. The Veteran's Awareness and Cooperation

The institutional frameworks that might, in theory, provide some recognition or remedy for women in this situation are almost entirely dependent on the veteran's participation. DVA claims require the veteran's engagement with the system. Family court proceedings involve the veteran as a party. AVO applications name the veteran as the respondent.

Where the veteran does not accept, or is not aware of, the quinoline nexus — where he attributes his behaviour to other causes, or does not recognise his behaviour as dangerous — the woman seeking recognition of harm is further constrained. She may be seeking to name a cause that the person most directly connected to it actively resists. That resistance is not necessarily deliberate. Anterograde amnesia is a documented effect of mefloquine intoxication. A veteran may have no reliable memory of episodes that the woman witnessed directly. This creates an evidentiary asymmetry that no current framework addresses.

6. Pathways to Redress

There is currently no pathway by which a woman in this situation can obtain formal recognition of harm. There is no pathway to compensation. There is no mechanism for retrospective clinical acknowledgement linking her health consequences to the veteran's drug exposure. There is no legislative instrument, no DVA policy, no RMA determination, and no court precedent that would support such a claim.

The harm is real. The causal chain is coherent and traceable. The institutional architecture required to respond to it does not exist.

In the absence of a DVA pathway, a legislative instrument, or a court precedent, a woman seeking recognition of harm has no clear avenue. She cannot lodge a claim. She cannot obtain a clinical record that names the cause. She cannot point to a prior case. She cannot identify an expert who has given evidence on this matter in an Australian court. She cannot access a compensation scheme. She cannot obtain acknowledgement from the institution — the Australian government — whose decision to administer these drugs without adequate consent, monitoring, or follow-up is the origin of the causal chain that ends with her injury.

Evidential Register

This register identifies the evidentiary basis for each category of claim in this document and provides direct links to source material. It is provided for the use of legal representatives, policy officers, clinicians, and researchers assessing the document's reliability.

Quinoline neurotoxicity and pharmacological effects Established in peer-reviewed literature.

Health consequences for partners Drawn inferentially from the general research literature on intimate partner violence and chronic interpersonal trauma. Direct studies of health outcomes in the ADF quinoline-exposed partner cohort have not been conducted.

Family court failures and pathologisation of protective mothers Drawn from general domestic violence and family court literature. No studies specific to the quinoline-affected partner cohort exist.

Veterans and domestic violence Drawn from general veteran IPV literature. No studies specific to the ADF quinoline-exposed cohort exist.

DVA policy and programs Drawn from publicly available DVA documentation.

Forensic and legal precedent No Australian precedent has been identified in which quinoline toxicity has been introduced as an explanatory or mitigating factor in family court, AVO, or criminal proceedings. Comparative jurisdictional references to Agent Orange, asbestos, and thalidomide litigation are cited as structural analogues establishing the legal architecture for government-substance-to-family-harm claims in principle. They are not direct precedents for the quinoline context.

Claims for which no evidential basis currently exists The following are identified as gaps rather than established findings. They represent the primary research needs for this population:

  • Prevalence of trauma presentations in the ADF quinoline-exposed partner cohort.

  • Health outcome data for this cohort.

  • Cumulative exposure effects for women who remained in the relationship for extended periods.

  • Clinical outcomes for women who sought help during the pre-recognition period (approximately 2000–2018).

  • Developmental and psychological outcomes for children of quinoline-affected veterans.

  • The experience of women whose access to appropriate help was denied or distorted by the absence of any quinoline-specific clinical or legal framework during the years of harm.

Closing Note

This document is a clinical and social profile. It is also a record of absence. The harm sustained by women who have lived with quinoline-affected veterans is consistent with what the general research literature on chronic interpersonal trauma would predict. It is severe. It is long-term. In many cases, particularly for women who carried this harm for years or decades before any institutional recognition existed, it is irreversible.

The harm has a specific cause. That cause is traceable to a government decision. The decision has been partially acknowledged in relation to the veteran. It has not been acknowledged at all in relation to the woman who lived alongside its consequences.

What is documented here is not a series of administrative gaps awaiting correction. It is a structural absence: a population that exists, a harm that is real and causally grounded, and institutions that do not, at present, see either.

Jacqualine Roche
Next

Living With a Cartel Man